GleamWall
中文EN

GOVX GeoVax Labs, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 832489 · Fiscal year ends 12/31

Financial factors as of 2026-03-31 (2026Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY-84.8%
TTM net income YoY12.8%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-2,523.4%
Net margin-2,507.3%
FCF margin-2,236.0%
EBITDA margin-2,515.9%

Returns

ROE-509.3%
ROA-309.3%
ROIC (approx.)—
Asset turnover0.12x

Leverage & solvency

Liabilities / assets83.4%
Debt / equity0.00x
Current ratio1.06x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.89x
Accruals ratio-33.6%
Payout ratio—
Capex / revenue1.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$2.49M$3.95M
R&D expense$18.12M$23.71M
SG&A expense$6.01M$5.39M
Operating income-$21.64M-$25.14M
Interest expense$0$21,375
Net income-$21.46M-$24.99M
EBITDA-$21.57M-$25.05M
EPS (basic)-22.40-120.46
EPS (diluted)——
Balance sheet
Cash & equivalents$3.09M$5.51M
Receivables$0$659,409
Current assets$5.31M$7.93M
PP&E, net$108,830$149,974
Total assets$6.34M$8.16M
Current liabilities$1.94M$3.11M
Total liabilities$2.52M$3.11M
Shareholders' equity$3.83M$5.05M
Shares outstanding72,173421,475
Cash flow statement
Operating cash flow-$21.47M-$24.68M
Capital expenditure$27,612$20,653
Free cash flow-$21.50M-$24.70M
Investing cash flow-$27,612-$20,653
Financing cash flow$19.08M$23.75M
Depreciation & amortization$68,756$95,368
Stock-based compensation$1.12M$528,644

Free plan shows the latest 2 periods; Pro shows all 24 🔒

· This company does not report gross profit in XBRL.

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.